FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008148263> ?p ?o ?g. }

• W2008148263 endingPage "e96408" @default.
• W2008148263 startingPage "e96408" @default.
• W2008148263 abstract "Matrix metalloproteinase-9 is elevated within the acutely injured murine spinal cord and blockade of this early proteolytic activity with GM6001, a broad-spectrum matrix metalloproteinase inhibitor, results in improved recovery after spinal cord injury. As matrix metalloproteinase-9 is likewise acutely elevated in dogs with naturally occurring spinal cord injuries, we evaluated efficacy of GM6001 solubilized in dimethyl sulfoxide in this second species. Safety and pharmacokinetic studies were conducted in naïve dogs. After confirming safety, subsequent pharmacokinetic analyses demonstrated that a 100 mg/kg subcutaneous dose of GM6001 resulted in plasma concentrations that peaked shortly after administration and were sustained for at least 4 days at levels that produced robust in vitro inhibition of matrix metalloproteinase-9. A randomized, blinded, placebo-controlled study was then conducted to assess efficacy of GM6001 given within 48 hours of spinal cord injury. Dogs were enrolled in 3 groups: GM6001 dissolved in dimethyl sulfoxide (n = 35), dimethyl sulfoxide (n = 37), or saline (n = 41). Matrix metalloproteinase activity was increased in the serum of injured dogs and GM6001 reduced this serum protease activity compared to the other two groups. To assess recovery, dogs were a priori stratified into a severely injured group and a mild-to-moderate injured group, using a Modified Frankel Scale. The Texas Spinal Cord Injury Score was then used to assess long-term motor/sensory function. In dogs with severe spinal cord injuries, those treated with saline had a mean motor score of 2 (95% CI 0–4.0) that was significantly (P<0.05; generalized linear model) less than the estimated mean motor score for dogs receiving dimethyl sulfoxide (mean, 5; 95% CI 2.0–8.0) or GM6001 (mean, 5; 95% CI 2.0–8.0). As there was no independent effect of GM6001, we attribute improved neurological outcomes to dimethyl sulfoxide, a pleotropic agent that may target diverse secondary pathogenic events that emerge in the acutely injured cord." @default.
• W2008148263 created "2016-06-24" @default.
• W2008148263 creator A5023049160 @default.
• W2008148263 creator A5031188468 @default.
• W2008148263 creator A5048523154 @default.
• W2008148263 creator A5049889876 @default.
• W2008148263 creator A5053910431 @default.
• W2008148263 creator A5056192079 @default.
• W2008148263 creator A5068434667 @default.
• W2008148263 creator A5072099288 @default.
• W2008148263 creator A5072806524 @default.
• W2008148263 creator A5073998761 @default.
• W2008148263 creator A5083221826 @default.
• W2008148263 date "2014-05-01" @default.
• W2008148263 modified "2023-10-13" @default.
• W2008148263 title "Efficacy of a Metalloproteinase Inhibitor in Spinal Cord Injured Dogs" @default.
• W2008148263 cites W1534280844 @default.
• W2008148263 cites W1632883247 @default.
• W2008148263 cites W1737750271 @default.
• W2008148263 cites W1905813109 @default.
• W2008148263 cites W1908112684 @default.
• W2008148263 cites W1963729509 @default.
• W2008148263 cites W1969576719 @default.
• W2008148263 cites W1976643053 @default.
• W2008148263 cites W1986510096 @default.
• W2008148263 cites W1996555111 @default.
• W2008148263 cites W1999706672 @default.
• W2008148263 cites W2001841294 @default.
• W2008148263 cites W2011257138 @default.
• W2008148263 cites W2013412099 @default.
• W2008148263 cites W2016937416 @default.
• W2008148263 cites W2020509002 @default.
• W2008148263 cites W2023351583 @default.
• W2008148263 cites W2023751372 @default.
• W2008148263 cites W2025212417 @default.
• W2008148263 cites W2025967875 @default.
• W2008148263 cites W2032541700 @default.
• W2008148263 cites W2032587684 @default.
• W2008148263 cites W2035980742 @default.
• W2008148263 cites W2037209188 @default.
• W2008148263 cites W2040690760 @default.
• W2008148263 cites W2044130940 @default.
• W2008148263 cites W2045414227 @default.
• W2008148263 cites W2047560524 @default.
• W2008148263 cites W2047596225 @default.
• W2008148263 cites W2049672678 @default.
• W2008148263 cites W2056679870 @default.
• W2008148263 cites W2070347443 @default.
• W2008148263 cites W2081476175 @default.
• W2008148263 cites W2081895687 @default.
• W2008148263 cites W2085674103 @default.
• W2008148263 cites W2087668336 @default.
• W2008148263 cites W2090465347 @default.
• W2008148263 cites W2092553754 @default.
• W2008148263 cites W2094791781 @default.
• W2008148263 cites W2096769354 @default.
• W2008148263 cites W2101966356 @default.
• W2008148263 cites W2103966320 @default.
• W2008148263 cites W2116447863 @default.
• W2008148263 cites W2120990276 @default.
• W2008148263 cites W2126486918 @default.
• W2008148263 cites W2135423586 @default.
• W2008148263 cites W2142958905 @default.
• W2008148263 cites W2143276442 @default.
• W2008148263 cites W2144623814 @default.
• W2008148263 cites W2149323108 @default.
• W2008148263 cites W2155567879 @default.
• W2008148263 cites W2169454631 @default.
• W2008148263 cites W2170645579 @default.
• W2008148263 cites W2326184101 @default.
• W2008148263 cites W4236805817 @default.
• W2008148263 cites W4242602991 @default.
• W2008148263 doi "https://doi.org/10.1371/journal.pone.0096408" @default.
• W2008148263 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4006832" @default.
• W2008148263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24788791" @default.
• W2008148263 hasPublicationYear "2014" @default.
• W2008148263 type Work @default.
• W2008148263 sameAs 2008148263 @default.
• W2008148263 citedByCount "29" @default.
• W2008148263 countsByYear W20081482632014 @default.
• W2008148263 countsByYear W20081482632015 @default.
• W2008148263 countsByYear W20081482632016 @default.
• W2008148263 countsByYear W20081482632017 @default.
• W2008148263 countsByYear W20081482632018 @default.
• W2008148263 countsByYear W20081482632019 @default.
• W2008148263 countsByYear W20081482632020 @default.
• W2008148263 countsByYear W20081482632021 @default.
• W2008148263 countsByYear W20081482632022 @default.
• W2008148263 countsByYear W20081482632023 @default.
• W2008148263 crossrefType "journal-article" @default.
• W2008148263 hasAuthorship W2008148263A5023049160 @default.
• W2008148263 hasAuthorship W2008148263A5031188468 @default.
• W2008148263 hasAuthorship W2008148263A5048523154 @default.
• W2008148263 hasAuthorship W2008148263A5049889876 @default.
• W2008148263 hasAuthorship W2008148263A5053910431 @default.
• W2008148263 hasAuthorship W2008148263A5056192079 @default.
• W2008148263 hasAuthorship W2008148263A5068434667 @default.
• W2008148263 hasAuthorship W2008148263A5072099288 @default.

• next